BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue growth accelerates
Q3 FY2026 cost of revenue of $205.42B rose 146536.7% year over year, ahead of the +35566.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 101192.4% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Cost of revenue amounted to 22.9% of revenue in FY2025, up 2.5 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +146536.7% holds above the trailing-twelve-month pace of +35566.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 736.83M USD
- Year-over-year change
- +27.0%
- 4-year CAGR
- +11.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 736.83M | +27.0% |
| FY2024 | 2024-12-31 | 580.24M | +9.1% |
| FY2023 | 2023-12-31 | 532.06M | +5.8% |
| FY2022 | 2022-12-31 | 503.02M | +6.9% |
| FY2021 | 2021-12-31 | 470.52M | — |
Cost of Revenue vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35566.9% is the highest of 11, against a peer median of +70.5%.
- Cost of revenue amounts to 20.1% of revenue for BMRN, versus a peer median of 13.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $206.11B USD | +35566.9% | +13.6% | 20.1% | |
| LTM Sep 2026 | $1.87B USD | +16.5% | +18.7% | 14.4% | |
| LTM Jun 2026 | $974.34M USD | +141.9% | +58.9% | 20.3% | |
| LTM Jun 2026 | $190.3M USD | +96.8% | +31.3% | 16.7% | |
| LTM Jun 2026 | $180.19M USD | +250.5% | +17.1% | 17.9% | |
| LTM Sep 2026 | €113.42M EUR | +32.9% | +104.1% | 9.4% | |
| LTM Mar 2026 | $109.99M USD | +25.2% | +56.7% | 16.4% | |
| LTM Jun 2026 | $47.45M USD | +428.8% | +101.9% | 6.7% | |
| LTM Mar 2026 | $46.97M USD | +32.9% | +37.5% | 12.7% | |
| LTM Sep 2026 | $31.49M USD | +204.6% | +32.7% | 4.8% | |
| LTM Sep 2026 | $17.04M USD | +44.2% | +4.3% | 1.8% | |
| Peer median (excluding BMRN) | — | +70.5% | +35.1% | 13.6% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.